Answer:
What are so called breast-cancer genes, are mutations in two genes: BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two), and are also associated with ovaric cancer. According to the question, these genes are present in the popolation despite surgeries and deaths, and asks why. Surgeries does not eliminate the genes, they eliminate the tumors, and people can still reproduce after that. And also, most people already had offspring before they know they have cancer, so they are inheriting the mutations on the genes anyway.
Explanation:
The answer is yes. Since trypanosomes do not enter cells, they are well exposed to antibodies of the immunity. They are not fully eradicated by the immune attack due to antigenic variations that enable some of its population to be unrecognized by antibodies. Keeping their surface antigen static would, therefore, improve eradication of Trypanosomiasis
The drug would be administered after infection. This is because the drug most likely works against the genes and metabolic/biological pathways of the trypanosomes responsible for their surface antigens. This would allow the immune system to easily form antibodies against the surface antigens. There would be no fear that the trypanosomes could vary their antigens hence evade the immune system.
Answer:
Answer is option C.
"This drug sometimes provides a complete cure of inflammatory bowel disease.''
Explanation:
- Crohn’s disease is a type of inflammatory bowel disease (IBD) that is caused by autoimmune or genetic factors. It affects any part of the gastrointestinal tract (from the mouth to the anus) and causes abdominal pain, fever, diarrhea, weight loss, etc.
- There is no known cure for Crohn's disease, but therapies can bring about long-term remission by greatly reducing the symptoms. For patients who have not had success with other medical therapies, Infliximab (Remicade) is used.
- Infliximab is a chimeric monoclonal antibody that binds to and neutralizes a key biologic response mediator called tumor necrosis factor-alpha (TNF-α) on the cell membrane and blocks its activity by destroying TNF-α producing cell, thus decreasing inflammation.
- For Crohn’s Disease, the FDA approved dose for adults is 5 mg/kg IV at 0, 2 and 6 weeks, then every 8 weeks.
- The common adverse reactions include urinary tract infections, upper respiratory infections and infusion-related reactions such as headache, fevers, chills, abdominal pain, diarrhea, nausea, hives, rash, shortness of breath, hypotension or hypertension, anaphylaxis, pruritus, convulsions, etc.
- Patients treated with infliximab are at increased risk for developing serious infections such as tuberculosis, fungal infections (histoplasmosis, candidiasis, blastomycosis, pneumocystosis, etc), bacterial, viral and other infections due to pathogens like Legionella and Listeria.
